News | Artificial Intelligence | September 03, 2019

Machine learning-based model uses texture analysis to identify whether thyroid nodules are benign or malignant

New Radiomics Model Uses Immunohistochemistry to Predict Thyroid Nodules

Workflow of radiomics analysis for IHC indicators. Yellow lines denote area of analysis; red lines denote ROI for radiomic features extraction. X = original image, L = low-pass filter, H = high-pass filter. Image courtesy of Jiabing Gu, et al.


September 3, 2019 — Researchers have validated a first-of-its-kind machine learning–based model to evaluate immunohistochemical (IHC) characteristics in patients with suspected thyroid nodules, according to an ahead-of-print article published in the December issue of the American Journal of Roentgenology (AJR).1 The research team achieved “excellent performance” for individualized noninvasive prediction of the presence of cytokeratin 19, galectin 3 and thyroperoxidase based upon computed tomography (CT) images.

“When IHC information is hidden on CT images,” principal investigator Jiabing Gu explained, “it may be possible to discern the relation between this information and radiomics by use of texture analysis.” 

To assess whether texture analysis could be utilized to predict IHC characteristics of suspected thyroid nodules, Gu and colleagues from China’s University of Jinan enrolled 103 patients (training cohort–to-validation cohort ratio, ≈ 3:1) with suspected thyroid nodules who had undergone thyroidectomy and IHC analysis from January 2013 to January 2016. All 103 patients — 28 men, 75 women; median age, 58 years; age range, 33–70 years — underwent CT before surgery, and 3D Slicer v 4.8.1 was used to analyze images of the surgical specimen.

To facilitate test-retest methods, 20 patients were imaged in two sets of CT series within 10–15 minutes, using the same scanner (LightSpeed 16, Philips Healthcare) and protocols, without contrast administration. These images were used only to select reproducible and nonredundant features, not to establish or verify the radiomic model. 

The Kruskal-Wallis test (SPSS v 19, IBM) was employed to improve classification performance between texture feature and IHC characteristic. Gu et al. considered characteristics with p < 0.05 significant, and the feature-based model was trained via support vector machine methods, assessed with respect to accuracy, sensitivity, specificity, corresponding AUC and independent validation. From 828 total features, 86 reproducible and nonredundant features were selected to build the model. 

The best performance of the cytokeratin 19 radiomic model yielded accuracy of 84.4 percent in the training cohort and 80 percent in the validation cohort. Meanwhile, the thyroperoxidase and galectin 3 predictive models evidenced accuracies of 81.4 percent and 82.5 percent in the training cohort, and 84.2 percent and 85 percent in the validation cohort, respectively. 

Noting that cytokeratin 19 and galectin 3 levels are high in papillary carcinoma, Gu maintained that these models can help radiologists and oncologists to identify papillary thyroid cancers, “which is beneficial for diagnosing papillary thyroid cancers earlier and choosing treatment options in a timely manner.”

Ultimately, asserted Gu, “this model may be used to identify benign and malignant thyroid nodules.”

For more information: www.ajronline.org

 

Reference

1. Gu J., Zhu J., Qiu Q., et al. Prediction of Immunohistochemistry of Suspected Thyroid Nodules by Use of Machine Learning–Based Radiomics. American Journal of Roentgenology, published online Aug. 28, 2019. DOI: 10.2214/AJR.19.21535


Related Content

News | Magnetic Resonance Imaging (MRI)

April 27 2026 — SimonMed, one of the nation’s largest independent outpatient imaging providers, has announced the ...

Time May 04, 2026
arrow
News | Radiation Oncology

April 27, 2026 — Radiation oncologists from across the country were in Washington in late April to warn lawmakers that ...

Time May 04, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Imaging Software Development

April 28, 2026 — Avatar Medical has been granted FDA 510(k) clearance for Avatar Medical Vision, its software platform ...

Time April 28, 2026
arrow
News | Cardiac Imaging

April 28, 2026 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next ...

Time April 28, 2026
arrow
News | FDA

April 16, 2026 — Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral ...

Time April 20, 2026
arrow
News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News | Computed Tomography (CT)

April 2, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for True ...

Time April 03, 2026
arrow
News | Ultrasound Imaging

March 30, 2026 — Butterfly Network, Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for a ...

Time April 01, 2026
arrow
News | Computed Tomography (CT)

March 30, 2026 — HCA Healthcare’s Good Samaritan Hospital is the first hospital in the Bay Area to implement Lumina 3D ...

Time April 01, 2026
arrow
Subscribe Now